PAM
TEVA icon

Premier Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Premier Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17,300
Closed -$574K – 114
2017
Q2 		$574K Hold
17,300
– – 0.13% 81
2017
Q1 		$555K Sell
17,300
-1,700
-9% -$58K 0.13% 81
2016
Q4 		$688K Buy
+19,000
New +$759K 0.18% 70

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Premier Asset Management's TEVA Position: Q3 2017 in Review

Premier Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 17,300 shares — an estimated $574K sold.

Premier Asset Management first reported a position in TEVA in Q4 2016 and held it in 3 quarters. The position peaked at $688K in Q4 2016. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Premier Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Premier Asset Management sold 17,300 Teva Pharmaceuticals shares in Q3 2017, an estimated $574K.
  • Premier Asset Management first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Premier Asset Management's Teva Pharmaceuticals position peaked at $688K in Q4 2016.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Premier Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.